Home » Newsletters » BioWorld Science

BioWorld Science

April 6, 2022

View Archived Issues

P-selectin associated with COVID-19 severity and mortality

BMP-9 is required for survival after acute myocardial infarction

VBI Vaccines reports new preclinical data from coronavirus program VBI-2900

Targinta selects TARG-9 as drug candidate

Discovery may allow more selective chemokine targeting

NUAK1 inhibition as new antifibrotic treatment strategy

Elevated troponin in patients with COVID-19 is an independent risk factor for mortality

OPG is an independent factor for coronary artery calcification in hypertension

Shaanxi Micot Technology discloses new CaSR agonists

New HBV antiviral compounds patented by Janssen

Gasherbrum Bio presents new GLP-1 receptor agonists

Schroedinger identifies new CDC7 inhibitors

New SPNS2 inhibitors synthesized by University of Virginia

PEAR1 genetic variation tied to big endothelin levels in patients with acute myocardial infarction

Atreca announces agreement with Zymeworks and selection of new clinical candidate

Can-Fite developing topical formulation of piclidenoson for the treatment of psoriasis

NOX2 inhibition reverses obesity-induced atrial fibrillation

N-LIfT results in complete cell killing in solid tumor organoids

ACE2-independent blood cell infection linked to severe COVID

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...